These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20699383)

  • 21. GH activity and markers of inflammation: a crossover study in healthy volunteers treated with GH and a GH receptor antagonist.
    Andreassen M; Frystyk J; Faber J; Kristensen LØ
    Eur J Endocrinol; 2012 May; 166(5):811-9. PubMed ID: 22408123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
    Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
    J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
    Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
    Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
    Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relationship among pathological change of gastric mucous, body mass index and the serum levels of ghrelin and leptin].
    Zhang J; Ding SG; Yang XL; Wang Y; Zhang HJ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Oct; 42(5):543-6. PubMed ID: 20957012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different effects of short- and long-term recombinant hGH administration on ghrelin and adiponectin levels in GH-deficient adults.
    Giavoli C; Cappiello V; Corbetta S; Ronchi CL; Morpurgo PS; Ferrante E; Beck-Peccoz P; Spada A
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):81-7. PubMed ID: 15212648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias.
    Auriemma RS; Pivonello R; De Martino MC; Cudemo G; Grasso LF; Galdiero M; Perone Y; Colao A
    Eur J Endocrinol; 2013 Jan; 168(1):15-22. PubMed ID: 23065994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study.
    Plöckinger U; Reuter T
    Eur J Endocrinol; 2008 Apr; 158(4):467-71. PubMed ID: 18362292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
    Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
    J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum leptin levels and GHR-d3/fl gene polymorphism in acromegalic patients with thyroid nodules.
    Topsakal S; Akin F; Turgut S; Yerlikaya E; Yaylali GF
    Adv Clin Exp Med; 2017; 26(2):281-286. PubMed ID: 28791847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects.
    Brian SR; Bidlingmaier M; Wajnrajch MP; Weinzimer SA; Inzucchi SE
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3374-7. PubMed ID: 17595256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues.
    De Martino MC; Auriemma RS; Brevetti G; Vitale G; Schiano V; Galdiero M; Grasso L; Lombardi G; Colao A; Pivonello R
    J Endocrinol Invest; 2010 Oct; 33(9):663-70. PubMed ID: 20595800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma levels of total and active ghrelin in acromegaly and growth hormone deficiency.
    Jarkovská Z; Rosická M; Marek J; Hána V; Weiss V; Justová V; Lacinová Z; Haluzík M; Krsek M
    Physiol Res; 2006; 55(2):175-181. PubMed ID: 15910166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insights from growth hormone receptor blockade.
    Muller AF; van der Lely AJ
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1072-9. PubMed ID: 15535428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant, specific determination of growth hormone and pegvisomant in human serum.
    Ørskov H; Frystyk J; Nielsen C; Hansen AT; Weeke J; Jørgensen JO
    Growth Horm IGF Res; 2007 Oct; 17(5):431-4. PubMed ID: 17574889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
    Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
    Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ghrelin administration affects circulating pituitary and gastro-entero-pancreatic hormones in acromegaly.
    Arosio M; Ronchi CL; Gebbia C; Pizzinelli S; Conte D; Cappiello V; Epaminonda P; Cesana BM; Beck-Peccoz P; Peracchi M
    Eur J Endocrinol; 2004 Jan; 150(1):27-32. PubMed ID: 14713276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
    Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
    Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
    J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
    van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
    J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.